The WHO Therapeutics and COVID-19: living guideline contains the Organization’s most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an online platform, an...
Inhibidores de las Cinasas Janus/uso terapéutico,
COVID-19/tratamiento farmacológico,
Antivirales/uso terapéutico,
Ivermectina/uso terapéutico,
Hidroxicloroquina/uso terapéutico,
Plasma/inmunología,
Fluvoxamina/uso terapéutico,
Colchicina/uso terapéutico,
Inmunización Pasiva,
Receptores de Interleucina-6/uso terapéutico,
Lopinavir/uso terapéutico,
Corticoesteroides/uso terapéutico
The WHO COVID-19 Clinical management: living guidance contains the Organization’s most up-to-date recommendations for the clinical management of people with COVID-19. Providing guidance that is comprehensive and holistic for the optimal care of COVID-19 patients throughout their entire illness is impor...
COVID-19/complicaciones,
COVID-19/diagnóstico,
Máscaras,
Salud Global,
Hospitalización,
Respiración Artificial,
Choque Séptico,
Lactancia Materna,
Embarazo,
Síndrome de Dificultad Respiratoria/etiología,
Neumonía Viral/etiología,
Cuidados Paliativos,
Rehabilitación,
Manejo de Atención al Paciente/organización & administración
El parto pretérmino en la región centroamericana tiene variaciones en cada país, así como
la mortalidad perinatal neonatal y materna que se deriva de la condición. La atención
adecuada sigue siendo una barrera en las zonas con más limitaciones en los servicios y el
personal sanitario disponible.
E...
Local reactions were reported by the majority of vaccine recipients and at higher rates than placebo recipients (75.3% vs 20.6% after dose 2). Pain/tenderness at the injection site was the most common and most severe local reaction among vaccine recipients and reported more frequently after dose 2 than a...
A Grading of Recommendations, Assessment, Development and Evaluation (GRADE) review of the evidence for benefits and harms for Moderna coronavirus disease 2019 (COVID-19) vaccine for persons aged 12-17 years was presented to the Advisory Committee for Immunization Practices (ACIP) on June 23, 2022. GRADE...
A Grading of Recommendations, Assessment, Development and Evaluation (GRADE) review of the evidence for benefits and harms for Moderna coronavirus disease 2019 (COVID-19) vaccine for children aged 6–11 years was presented to the Advisory Committee for Immunization Practices (ACIP) on June 23, 2022. GRA...
The Advisory Committee on Immunization Practices (ACIP) provides advice and guidance to the Director of the CDC regarding use of vaccines and related agents for control of vaccine-preventable diseases in the civilian population of the United States. Recommendations made by the ACIP are reviewed by the CD...
A Grading of Recommendations, Assessment, Development and Evaluation (GRADE) review of the evidence for benefits and harms for Novavax coronavirus disease 2019 (COVID-19) vaccine was presented to the Advisory Committee on Immunization Practices (ACIP) on July 19, 2022. GRADE evidence type indicates the c...
A Grading of Recommendations, Assessment, Development and Evaluation (GRADE) review of the evidence for benefits and harms for Novavax coronavirus disease 2019 (COVID-19) vaccine was presented to the Advisory Committee on Immunization Practices (ACIP) on July 19, 2022. GRADE evidence type indicates the c...
The emergence of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), in late 2019 has led to a global pandemic with dramatic societal and economic impact on individual persons and communities. In the United States, more than 89 million cases and more than 1 million COVID-19-associated ...
